Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hammond

Showing results (671-680 of 711) with videos related to

Pageof 72
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative studyAnthony W Tolcher, Leonel Ochoa, Lisa A Hammond, et al.
Nature Human Behaviour|June 29, 2021
A review and agenda for integrated disease models including social and behavioural factorsJamie Bedson, Laura A Skrip, Danielle Pedi, et al.
American Journal of Pharmaceutical Education|July 20, 2017
Perceived Motivating Factors and Barriers for the Completion of Postgraduate Training Among American Pharmacy Students Prior to Beginning Advanced Pharmacy Practice ExperiencesDrayton A Hammond, Douglas R Oyler, John W Devlin, et al.
The Journal of Experimental Medicine|April 26, 2022
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissueZhi Li, Zewen K Tuong, Isaac Dean, et al.
Cancer Immunology Research|June 16, 2025
In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 BlockadeColin Y C Lee, Isaac Dean, Nathan Richoz, et al.
Circulation. Heart Failure|March 11, 2018
Long-Term Cognitive Decline After Newly Diagnosed Heart Failure: Longitudinal Analysis in the CHS (Cardiovascular Health Study)Christa A Hammond, Natalie J Blades, Sarwat I Chaudhry, et al.
Mabs|January 5, 2021
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancerDarren J Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, et al.
Blood Advances|November 8, 2019
Replication timing alterations in leukemia affect clinically relevant chromosome domainsJuan Carlos Rivera-Mulia, Takayo Sasaki, Claudia Trevilla-Garcia, et al.
Cancer Biology & Therapy|January 11, 2024
Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor modelsBrajesh P Kaistha, Gozde Kar, Andreas Dannhorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2000
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignanciesS G Eckhardt, S D Baker, C D Britten, et al.
Pageof 72

Showing results (671-680 of 711) with videos related to

Sort By:
Pageof 72
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative studyAnthony W Tolcher, Leonel Ochoa, Lisa A Hammond, et al.
Nature Human Behaviour|June 29, 2021
A review and agenda for integrated disease models including social and behavioural factorsJamie Bedson, Laura A Skrip, Danielle Pedi, et al.
American Journal of Pharmaceutical Education|July 20, 2017
Perceived Motivating Factors and Barriers for the Completion of Postgraduate Training Among American Pharmacy Students Prior to Beginning Advanced Pharmacy Practice ExperiencesDrayton A Hammond, Douglas R Oyler, John W Devlin, et al.
The Journal of Experimental Medicine|April 26, 2022
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissueZhi Li, Zewen K Tuong, Isaac Dean, et al.
Cancer Immunology Research|June 16, 2025
In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 BlockadeColin Y C Lee, Isaac Dean, Nathan Richoz, et al.
Circulation. Heart Failure|March 11, 2018
Long-Term Cognitive Decline After Newly Diagnosed Heart Failure: Longitudinal Analysis in the CHS (Cardiovascular Health Study)Christa A Hammond, Natalie J Blades, Sarwat I Chaudhry, et al.
Mabs|January 5, 2021
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancerDarren J Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, et al.
Blood Advances|November 8, 2019
Replication timing alterations in leukemia affect clinically relevant chromosome domainsJuan Carlos Rivera-Mulia, Takayo Sasaki, Claudia Trevilla-Garcia, et al.
Cancer Biology & Therapy|January 11, 2024
Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor modelsBrajesh P Kaistha, Gozde Kar, Andreas Dannhorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2000
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignanciesS G Eckhardt, S D Baker, C D Britten, et al.
Pageof 72